Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment

OBJECTIVE: We previously reported that 2 years of costimulation modulation with abatacept slowed decline of β-cell function in recent-onset type 1 diabetes (T1D). Subsequently, abatacept was discontinued and subjects were followed to determine whether there was persistence of effect. RESEARCH DESIGN...

Descripción completa

Detalles Bibliográficos
Autores principales: Orban, Tihamer, Bundy, Brian, Becker, Dorothy J., DiMeglio, Linda A., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Greenbaum, Carla J., Marks, Jennifer B., Monzavi, Roshanak, Moran, Antoinette, Peakman, Mark, Raskin, Philip, Russell, William E., Schatz, Desmond, Wherrett, Diane K., Wilson, Darrell M., Krischer, Jeffrey P., Skyler, Jay S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2014
Materias:
Emerging Technologies and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964491/
https://www.ncbi.nlm.nih.gov/pubmed/24296850
http://dx.doi.org/10.2337/dc13-0604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964491/
https://www.ncbi.nlm.nih.gov/pubmed/24296850
http://dx.doi.org/10.2337/dc13-0604

Ejemplares similares